Published in parts as a poster at 121. Kongress der Deutschen Gesellschaft für Chirurgie 27.4.2004 at Berlin/Germany.
Is surgery-only the adequate treatment approach for T2N0 rectal cancer?†
Article first published online: 20 MAR 2006
Copyright © 2006 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 93, Issue 5, pages 350–354, 1 April 2006
How to Cite
Petersen, S., Hellmich, G., von Mildenstein, K., Porse, G. and Ludwig, K. (2006), Is surgery-only the adequate treatment approach for T2N0 rectal cancer?. J. Surg. Oncol., 93: 350–354. doi: 10.1002/jso.20452
- Issue published online: 20 MAR 2006
- Article first published online: 20 MAR 2006
- Manuscript Accepted: 4 NOV 2005
- Manuscript Received: 25 AUG 2004
- rectal cancer;
- tumor localization;
- local recurrence;
- adjuvant treatment
Background and Objectives
Resection combined with standard lymphadenectomy is generally recommended for T2N0 rectal cancer. In order to evaluate the outcome of this specific tumor category, our own data were reviewed.
To evaluate the results of patients with curative resected T2N0 rectal carcinoma, we reviewed data of 164 consecutive patients with adenocarcinoma of the rectum between 1981 and 2003 in our department. In addition, patient characteristics were stratified according to the position of the rectal tumor with respect to the anal verge.
One hundred ten patients (67.1%) underwent anterior resection and 54 patients (32.9%) received abdominoperineal amputation. The follow-up revealed 6 local recurrences (3.7%); in 10 patients (10.0%), metastases were discovered. Regarding the tumor localization nearly no local recurrence or distant metastases were observed in the middle or the upper rectum. However, in the lower rectum the actuarial 5-year recurrence rate was 16.2%.
Although T2N0 rectal carcinomas are considered as low risk tumors, we found a considerable local recurrence rate of 3.7%. The question arises whether this result can be improved by adjuvant treatment modalities without being compromised by the toxicity of an adjuvant treatment. J. Surg. Oncol. 2006;93:350–354. © 2006 Wiley-Liss, Inc.